Table 3 Overview of antispastic therapies and measures during the study
From: Quality of life and costs of spasticity treatment in German stroke patients
IncobotulinumtoxinA group: Antispastic medications except BoNT/A, non-pharmacological therapies and aids | ||||
First quarter (n = 108) | Second quarter (n = 102) | Third quarter (n = 99) | Fourth quarter (n = 94) | |
Oral medication | 31 (28.7 %) | 23 (32.4 %) | 20 (20.2 %) | 18 (19.1 %) |
Physical therapy | 60 (55.6 %) | 54 (52.9 %) | 54 (54.5 %) | 51 (54.3 %) |
Occupational therapy | 43 (39.8 %) | 42 (41.2 %) | 41 (41.4 %) | 44 (46.8 %) |
Speech therapy | 10 (9.3 %) | 8 (7.8 %) | 8 (8.1 %) | 9 (8.6 %) |
Other therapies | 3 (2.8 %) | 6 (6.0 %) | 4 (4.0 %) | 4 (4.3 %) |
Therapeutic aids | 12 (11.0 %) | 5 (5.7 %) | - | 1 (1.0 %) |
Conventional therapy group: Antispastic medications, non-pharmacological therapies and aids | ||||
First quarter (n = 110) | Second quarter (n = 98) | Third quarter (n = 91) | Fourth quarter (n = 84) | |
Oral medication | 67 (60.9 %) | 66 (67.3 %) | 63 (69.2 %) | 58 (69.0 %) |
Physical therapy | 68 (61.8 %) | 59 (60.2 %) | 54 (54.5 %) | 52 (61.9 %) |
Occupational therapy | 15 (13.6 %) | 11 (11.2 %) | 11 (12.1 %) | 8 (9.5 %) |
Speech therapy | 5 (4.6 %) | 5 (5.1 %) | 5 (5.5 %) | 4 (4.8 %) |
Other therapies | 3 (2.7 %) | 5 (5.1 %) | - | 1 (1.2 %) |
Therapeutic aids | 10 (11.0 %) | 8 (8.2 %) | 12 (13.2 %) | 8 (9.5 %) |